New York, October 20, 2014 -- Moody's Investors Service upgraded Catalent Pharma Solutions, Inc.'s ("Catalent") Corporate Family Rating to B1 from B2, Probability of Default rating to B1-PD from B2-PD and Senior Unsecured Term loan rating to B3 from Caa1. Moody's also affirmed the company's Speculative Grade Liquidity rating of SGL-2. The rating outlook is positive. These rating actions follow Catalent's successful initial public offering and subsequent debt repayment of more than $870 million. This concludes the rating review that was initiated on July 31, 2014.

Vollständigen Artikel bei Moodys lesen